Summary
Global
Markets Direct's, 'Alzheimer's Disease - Pipeline Review, H2 2016', provides an
overview of the Alzheimer's Disease pipeline landscape.
The
report provides comprehensive information on the therapeutics under development
for Alzheimer's Disease, complete with analysis by stage of development, drug
target, mechanism of action (MoA), route of administration (RoA) and molecule
type. The report also covers the descriptive pharmacological action of the
therapeutics, its complete research and development history and latest news and
press releases. Additionally, the report provides an overview of key players
involved in therapeutic development for Alzheimer's Disease and features
dormant and discontinued projects.
Global
Markets Direct's report features investigational drugs from across globe covering
over 20 therapy areas and nearly 3,000 indications. The report is built using
data and information sourced from Global Markets Direct's proprietary
databases, company/university websites, clinical trial registries, conferences,
SEC filings, investor presentations and featured press releases from
company/university sites and industry-specific third party sources. Drug
profiles featured in the report undergoes periodic review following a stringent
set of processes to ensure that all the profiles are updated with the latest
set of information. Additionally, various dynamic tracking processes ensure
that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Buy a Sample copy of This Report @ http://www.radiantinsights.com/research/alzheimer-s-disease-pipeline-review-h2-2016/request-sample
No comments:
Post a Comment